Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

Seymour, Matthew; Brown, S. R.; Richman, Susan D.; Middleton, G. W.; Maughan, T; Olivier, C; Gwyther, Stephen J.; Wadsley, Jonathan; Chau, I.; Hickish, Tamas; Dawson, L.; Falk, S.; O’Callaghan, Ann; Benstead, Kim; Wadd, Nick; Oliver, Alfred; Chambers, Pinkie; Marshall, Henry; Napp, Vicky; Quirke, Philip

doi:10.1200/jco.2011.29.15_suppl.3523

Cited by 19 publications

(7 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several retrospective studies also suggested the role of BRAF as a marker of resistance to the EGFR-directed therapy in patients with metastatic CRC who experienced progression on the first-line therapy [ 50 – 53 ]. Furthermore, recent prospective data from the PICCOLO trial consistently reported the dismal effect of panitumumab combined with irinotecan on patient with BRAF mutations in the subsequent lines setting of chemotherapy [ 54 ]. Based on these results, BRAF mutation is now suggested as a prognostic factor in patients with CRC, and current guideline recommends genotyping of the gene at diagnosis of stage IV disease.…”

Section: Egfr-targeted Therapiesmentioning

confidence: 99%

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Lee

2016

BioMed Research International

View full text Add to dashboard Cite

Despite being one of the most frequently diagnosed cancers worldwide, prognosis of metastatic colorectal cancer (CRC) was poor. Development and introduction of biologic agents in treatment of patients with metastatic CRC have brought improved outcomes. Monoclonal antibodies directing epidermal growth factor receptors and vascular endothelial growth factor are main biologic agents currently used in treatment of metastatic CRC. Encouraged by results from many clinical trials demonstrating efficacy of those monoclonal antibodies, the combination therapy with those targeted agents and conventional chemotherapeutic agents has been established as the standard therapy for patients with metastatic CRC. However, emergency of resistance to those target agents has limited the efficacy of treatment, and strategies to overcome the resistance are now being investigated by newly developed biological techniques clarifying how to acquire resistance. Here, we introduce mechanisms of action of the biologic agents currently used for treatment of metastatic CRC and several landmark historical clinical studies which have changed the main stream of treatment. The mechanism of resistance to those agents, one of serious problems in treatment metastatic CRC, and ongoing clinical trials to overcome the limitations and improve treatment outcomes will also be presented in this review.

show abstract

Section: Egfr-targeted Therapiesmentioning

confidence: 99%

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Lee

2016

BioMed Research International

View full text Add to dashboard Cite

show abstract

“…At present, there is a paucity of evidence to warrant mutation testing in the clinical setting (Downward 2003). There is the suggestion of an association of NRAS mutations with a lower response to cetuximab and panitumumab from retrospective trial analyses (De Roock et al 2010), and this is supported by emerging data from the PICCOLO study (Seymour et al 2011a;De Mattos-Arruda et al 2011). …”

Section: Kras Mutationsmentioning

confidence: 90%

“…An association has been seen between BRAF V600E mutations and resistance to cetuximab in chemorefractory mCRC (Laurent-Puig et al 2009), supported by randomized trial data of a lesser benefit from cetuximab in patients whose tumors harbored a BRAF V600E mutation (Bokemeyer et al 2011;Van Cutsem et al 2011b). Initial results from the PICCOLO study examining the value of panitumumab in combination with irinotecan chemotherapy have demonstrated that patients whose tumors have a BRAF mutation do not benefit from the addition of panitumumab and may in fact experience a detrimental effect (Seymour et al 2011a). …”

Section: Kras Mutationsmentioning

confidence: 93%

Biomarkers in Metastatic Colorectal Cancer

Diakos

Charles

Chua

et al. 2014

Biomarkers in Cancer

View full text Add to dashboard Cite

Significant advances in chemotherapeutics over the past decade have seen a doubling in the median survival time of patients with metastatic colorectal cancer. However, this comes at the cost of toxicity to the patient and financial burden to the community. Biomarkers to predict disease course and treatment response are therefore of major importance so as to allow for the judicious selection of treatment candidates and agents and doses. This review seeks to summarize the current markers available for the prediction of prognosis and treatment response in metastatic colorectal cancer.

show abstract

“…The randomized multicenter PICCOLO trial, which assessed the safety and efficacy of irinotecan plus P, did not meet its primary end point of improved OS [76]. Even if there are no data support switching to either C or P after failure of the drug and guidelines are against this practice at the last ASCO annual meeting have been reported results from a retrospective analysis conducted on 25 mCRC patients with failed C treatment and undergone treatment with P. This analysis showed minimal benefit of P in this setting of patients, but prospective studies are required to adopt this clinical practice [77].…”

Section: Anti-egfr Moabs Against Gi Cancersmentioning

confidence: 98%

From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors

et al. 2014

View full text Add to dashboard Cite

In recent years, significant progress has been made in the diagnosis and treatment of gastrointestinal cancers. Researches and clinicians however are still faced with challenges, not the least is the detection and management of tumors with varied gene mutation status. Clarification of the molecular pathology of gastrointestinal cancers may improve treatment options as well as quality of life and the long-term survival of this patient class. Therefore, molecular-targeted therapies have emerged as clinically useful drugs for gastrointestinal cancers cure, and predictive biomarkers have been heralded as the way to develop the right drug for the right patient. Moving from such appealing molecular background, we wrote an overview of the main targeted therapies, with particular interest to monoclonal antibodies that have already been approved in clinical practice or are being tested in gastrointestinal cancers treatment.

show abstract

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

Cited by 19 publications

References 0 publications

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Advances of Targeted Therapy in Treatment of Unresectable Metastatic Colorectal Cancer

Biomarkers in Metastatic Colorectal Cancer

From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors

Contact Info

Product

Resources

About